PEN Stock Analysis: Penumbra | NYSE
Medical Devices | NYSE, USA | Market Cap: 12.530m USD | 12M Return: 30.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 112M
EPS Trend: 90.2%
Qual. Beats: -1
Rev. Trend: 99.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Penumbra, Inc. is a U.S.-based medical device company founded in 2004 and headquartered in Alameda, California. Listed on the NYSE since 2015 under the ticker PEN, the company operates within the Health Care Equipment sub-industry and develops, manufactures, and markets devices sold through direct sales organizations and distributors in the United States and internationally.
The companys product portfolio focuses primarily on vascular and neurovascular interventions, with three main franchises: thrombectomy systems (for the removal of blood clots, including the Indigo, Lightning, and CAT RX product lines), embolization products (for treating aneurysms and vascular lesions using coil and occlusion devices), and access products (guide and delivery catheters). It also offers neurosurgical tools such as the Artemis Neuro Evacuation Device.
As a medical device manufacturer, Penumbras business model is characterized by ongoing investment in product development and clinical evidence to support adoption of its technologies in hospital-based settings. The medical device sector is subject to regulatory oversight (such as FDA clearance in the U.S.) and reimbursement decisions by payers, both of which directly affect commercialization timelines and market access for new devices.
- Lightning Flash and Bolt 7 drive vascular thrombectomy revenue growth
- Inari Medical competition pressures vascular thrombectomy market share
- Neurovascular stroke procedure volume drives U.S. revenue growth
| Net Income: 171.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 1.77 > 1.0 |
| NWC/Revenue: 73.14% < 20% (prev 67.82%; Δ 5.32% < -1%) |
| CFO/TA 0.15 > 3% & CFO 276.7m > Net Income 171.0m |
| Net Debt (-25.1m) to EBITDA (221.0m): -0.11 < 3 |
| Current Ratio: 6.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (39.5m) vs 12m ago 0.97% < -2% |
| Gross Margin: 67.38% > 18% (prev 63.68%; Δ 3.70% > 0.5%) |
| Asset Turnover: 83.30% > 50% (prev 77.83%; Δ 5.47% > 0%) |
| Interest Coverage Ratio: 156.0 > 6 (EBIT TTM 203.9m / Interest Expense TTM 1.31m) |
| A: 0.56 (Total Current Assets 1.28b - Total Current Liabilities 211.7m) / Total Assets 1.90b |
| B: 0.14 (Retained Earnings 270.3m / Total Assets 1.90b) |
| C: 0.12 (EBIT TTM 203.9m / Avg Total Assets 1.75b) |
| D: 3.47 (Book Value of Equity 1.47b / Total Liabilities 424.6m) |
| Altman-Z'' = 8.57 = AAA |
| DSRI: 0.93 (Receivables 183.3m/168.0m, Revenue 1.45b/1.24b) |
| GMI: 0.95 (GM 63.68% / 67.38%) |
| AQI: 0.77 (AQ_t 0.15 / AQ_t-1 0.20) |
| SGI: 1.17 (Revenue 1.45b / 1.24b) |
| TATA: -0.06 (NI 171.0m - CFO 276.7m) / TA 1.90b) |
| Beneish M = -3.15 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 318.10 with a total of 146,602 shares traded. Over the past week, the price has changed by -0.15%, over one month by -0.39%, over three months by -3.54% and over the past year by +30.44%.
Current recommended Stop Loss: 314.10 (which is 1.3% or 1.8 ATR below the current price).
Penumbra has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy PEN.
- StrongBuy: 12
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 364.4 | 14.6% |
P/E Trailing = 73.5728
P/E Forward = 62.8931
P/S = 8.6158
P/B = 8.5016
P/EG = 4.0804
Revenue TTM = 1.45b USD
EBIT TTM = 203.9m USD
EBITDA TTM = 221.0m USD
Long Term Debt = 20.7m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 216.2m USD (from shortLongTermDebtTotal, last quarter) (leases 216.2m already included)
Net Debt = -25.1m USD (calculated: Debt 216.2m - CCE 241.3m)
Enterprise Value = 12.5b USD (12.5b + Debt 216.2m - CCE 241.3m)
Interest Coverage Ratio = 156.0 (Ebit TTM 203.9m / Interest Expense TTM 1.31m)
EV/FCF = 58.78x (Enterprise Value 12.5b / FCF TTM 212.7m)
FCF Yield = 1.70% (FCF TTM 212.7m / Enterprise Value 12.5b)
FCF Margin = 14.63% (FCF TTM 212.7m / Revenue TTM 1.45b)
Net Margin = 11.76% (Net Income TTM 171.0m / Revenue TTM 1.45b)
Gross Margin = 67.38% ((Revenue TTM 1.45b - Cost of Revenue TTM 474.3m) / Revenue TTM)
Gross Margin QoQ = 67.62% (prev 68.02%)
Tobins Q-Ratio = 6.59 (Enterprise Value 12.5b / Total Assets 1.90b)
Interest Expense / Debt = 0.60% (Interest Expense 1.31m / Debt 216.2m)
Taxrate = 15.72% (31.9m / 203.0m)
NOPAT = 171.9m (EBIT 203.9m * (1 - 15.72%))
Current Ratio = 6.02 (Total Current Assets 1.28b / Total Current Liabilities 211.7m)
Debt / Equity = 0.15 (Debt 216.2m / totalStockholderEquity, last quarter 1.47b)
Debt / EBITDA = -0.11 (Net Debt -25.1m / EBITDA 221.0m)
Debt / FCF = -0.12 (Net Debt -25.1m / FCF TTM 212.7m)
Total Stockholder Equity = 1.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.80% (Net Income 171.0m / Total Assets 1.90b)
RoE = 12.32% (Net Income TTM 171.0m / Total Stockholder Equity 1.39b)
RoCE = 14.47% (EBIT 203.9m / Capital Employed (Equity 1.39b + L.T.Debt 20.7m))
RoIC = 10.54% (NOPAT 171.9m / Invested Capital 1.63b)
WACC = 8.02% (E(12.5b)/V(12.7b) * Re(8.15%) + D(216.2m)/V(12.7b) * Rd(0.60%) * (1-Tc(0.16)))
Discount Rate = 8.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 37.78 | Cagr: 0.29%
[DCF] Terminal Value 77.97% ; FCFF base≈187.8m ; Y1≈215.2m ; Y5≈316.8m
[DCF] Fair Price = 121.8 (EV 4.77b - Net Debt -25.1m = Equity 4.79b / Shares 39.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 90.22 | EPS CAGR: 57.13% | SUE: -4.0 | # QB: -1
Revenue Correlation: 99.48 | Revenue CAGR: 16.00% | SUE: 0.48 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.18 | Chg30d=+1.78% | Revisions=-62% | Analysts=14
EPS next Quarter (2026-09-30): EPS=1.29 | Chg30d=+1.37% | Revisions=-62% | Analysts=14
EPS current Year (2026-12-31): EPS=4.97 | Chg30d=+1.63% | Revisions=-22% | GrowthEPS=+29.5% | GrowthRev=+13.9%
EPS next Year (2027-12-31): EPS=6.27 | Chg30d=-0.28% | Revisions=-67% | GrowthEPS=+26.1% | GrowthRev=+12.5%
[Analyst] Revisions Ratio: -72% (up=2, down=20)